{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:31:50Z","timestamp":1783110710524,"version":"3.54.6"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100023960","name":"National Institutes of Health - Department of Bioethics","doi-asserted-by":"publisher","award":["R01AG059008"],"award-info":[{"award-number":["R01AG059008"]}],"id":[{"id":"10.13039\/100023960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023960","name":"National Institutes of Health - Department of Bioethics","doi-asserted-by":"publisher","award":["R01AG073212"],"award-info":[{"award-number":["R01AG073212"]}],"id":[{"id":"10.13039\/100023960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023960","name":"National Institutes of Health - Department of Bioethics","doi-asserted-by":"publisher","award":["P30 AG072980"],"award-info":[{"award-number":["P30 AG072980"]}],"id":[{"id":"10.13039\/100023960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["GC-2013717"],"award-info":[{"award-number":["GC-2013717"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009797","name":"Barrow Neurological Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009797","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40120-025-00884-x","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:44:48Z","timestamp":1768808688000},"page":"479-496","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dementia in Progressive Supranuclear Palsy: A Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Kathleen S.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara S.","family":"Stipho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicki","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly A.","family":"Shill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal J.","family":"Abrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Eagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Decourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8139-3309","authenticated-orcid":false,"given":"Marwan N.","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"4","key":"884_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/archneur.1964.00460160003001","volume":"10","author":"JC Steele","year":"1964","unstructured":"Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10(4):333\u201359.","journal-title":"Arch Neurol"},{"issue":"6","key":"884_CR2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853\u201364.","journal-title":"Mov Disord"},{"issue":"Pt 6","key":"884_CR3","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/brain\/awh488","volume":"128","author":"DR Williams","year":"2005","unstructured":"Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson\u2019s syndrome and PSP-parkinsonism. Brain. 2005;128(Pt 6):1247\u201358.","journal-title":"Brain"},{"issue":"6","key":"884_CR4","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1212\/01.WNL.0000052991.70149.68","volume":"60","author":"U Nath","year":"2003","unstructured":"Nath U, Ben-Shlomo Y, Thomson RG, et al. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology. 2003;60(6):910\u20136.","journal-title":"Neurology"},{"issue":"Suppl 2","key":"884_CR5","first-page":"II1","volume":"246","author":"I Litvan","year":"1999","unstructured":"Litvan I, Grimes DA, Lang AE, et al. Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol. 1999;246(Suppl 2):II1\u20135.","journal-title":"J Neurol"},{"issue":"Pt 8","key":"884_CR6","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awq158","volume":"133","author":"RG Brown","year":"2010","unstructured":"Brown RG, Lacomblez L, Landwehrmeyer BG, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain. 2010;133(Pt 8):2382\u201393.","journal-title":"Brain"},{"issue":"2","key":"884_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/arclin\/acs098","volume":"28","author":"A Gerstenecker","year":"2013","unstructured":"Gerstenecker A, Mast B, Duff K, et al. Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy. Arch Clin Neuropsychol. 2013;28(2):104\u201313.","journal-title":"Arch Clin Neuropsychol"},{"issue":"5","key":"884_CR8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/jnen\/nlad025","volume":"82","author":"ED Driver-Dunckley","year":"2023","unstructured":"Driver-Dunckley ED, Zhang N, Serrano GE, et al. Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy. J Neuropathol Exp Neurol. 2023;82(5):438\u201351.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"9","key":"884_CR9","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/brainsci12091126","volume":"12","author":"Y Barer","year":"2022","unstructured":"Barer Y, Chodick G, Cohen R, et al. Epidemiology of progressive supranuclear palsy: real world data from the second largest health plan in Israel. Brain Sci. 2022;12(9):1126.","journal-title":"Brain Sci"},{"issue":"9","key":"884_CR10","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1007\/s00415-023-11791-2","volume":"270","author":"S Lyons","year":"2023","unstructured":"Lyons S, Trepel D, Lynch T, et al. The prevalence and incidence of progressive supranuclear palsy and corticobasal syndrome: a systematic review and meta-analysis. J Neurol. 2023;270(9):4451\u201365.","journal-title":"J Neurol"},{"issue":"6","key":"884_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/mdc3.12678","volume":"5","author":"M Mamarabadi","year":"2018","unstructured":"Mamarabadi M, Razjouyan H, Golbe LI. Is the latency from progressive supranuclear palsy onset to diagnosis improving? Mov Disord Clin Pract. 2018;5(6):603\u20136.","journal-title":"Mov Disord Clin Pract"},{"issue":"2","key":"884_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","volume":"140","author":"GG Kovacs","year":"2020","unstructured":"Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 2020;140(2):99\u2013119.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"884_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00533-z","volume":"17","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wu KM, Yang L, et al. Tauopathies: new perspectives and challenges. Mol Neurodegener. 2022;17(1):28.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"884_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1523\/JNEUROSCI.2305-16.2016","volume":"37","author":"V Lacovich","year":"2017","unstructured":"Lacovich V, Espindola SL, Alloatti M, et al. Tau isoforms imbalance impairs the axonal transport of the amyloid precursor protein in human neurons. J Neurosci. 2017;37(1):58\u201369.","journal-title":"J Neurosci"},{"issue":"1","key":"884_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3233\/JPD-202302","volume":"11","author":"Y Wen","year":"2021","unstructured":"Wen Y, Zhou Y, Jiao B, Shen L. Genetics of progressive supranuclear palsy: a review. J Parkinsons Dis. 2021;11(1):93\u2013105.","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"884_CR16","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1002\/alz.13784","volume":"20","author":"S Buchholz","year":"2024","unstructured":"Buchholz S, Zempel H. The six brain-specific TAU isoforms and their role in Alzheimer\u2019s disease and related neurodegenerative dementia syndromes. Alzheimers Dement. 2024;20(5):3606\u201328.","journal-title":"Alzheimers Dement"},{"issue":"14","key":"884_CR17","doi-asserted-by":"publisher","first-page":"13520","DOI":"10.1074\/jbc.M413490200","volume":"280","author":"SF Levy","year":"2005","unstructured":"Levy SF, Leboeuf AC, Massie MR, et al. Three- and four-repeat tau regulate the dynamic instability of two distinct microtubule subpopulations in qualitatively different manners. Implications for neurodegeneration. J Biol Chem. 2005;280(14):13520\u20138.","journal-title":"J Biol Chem"},{"issue":"1","key":"884_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nan.12208","volume":"41","author":"GG Kovacs","year":"2015","unstructured":"Kovacs GG. Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol. 2015;41(1):3\u201323.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"884_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2025.102536","volume":"112","author":"A Hattiholi","year":"2025","unstructured":"Hattiholi A, Hegde H, Shetty SK. Tauopathies: emerging discoveries on tau protein, with a special focus on Alzheimer\u2019s disease. Neuropeptides. 2025;112:102536.","journal-title":"Neuropeptides"},{"issue":"2","key":"884_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1523\/JNEUROSCI.2281-17.2017","volume":"38","author":"S Biswas","year":"2018","unstructured":"Biswas S, Kalil K. The microtubule-associated protein tau mediates the organization of microtubules and their dynamic exploration of actin-rich lamellipodia and filopodia of cortical growth cones. J Neurosci. 2018;38(2):291\u2013307.","journal-title":"J Neurosci"},{"issue":"9","key":"884_CR21","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1007\/s00415-021-10511-y","volume":"268","author":"A Horta-Barba","year":"2021","unstructured":"Horta-Barba A, Pagonabarraga J, Martinez-Horta S, et al. Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes. J Neurol. 2021;268(9):3400\u20138.","journal-title":"J Neurol"},{"issue":"2","key":"884_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1136\/jnnp.37.2.121","volume":"37","author":"ML Albert","year":"1974","unstructured":"Albert ML, Feldman RG, Willis AL. The \u201csubcortical dementia\u201d of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1974;37(2):121\u201330.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7880","key":"884_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","volume":"598","author":"Y Shi","year":"2021","unstructured":"Shi Y, Zhang W, Yang Y, et al. Structure-based classification of tauopathies. Nature. 2021;598(7880):359\u201363.","journal-title":"Nature"},{"issue":"Suppl 2","key":"884_CR24","doi-asserted-by":"publisher","first-page":"II6","DOI":"10.1007\/BF03161076","volume":"246","author":"DW Dickson","year":"1999","unstructured":"Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol. 1999;246(Suppl 2):II6\u201315.","journal-title":"J Neurol"},{"issue":"1","key":"884_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-018-0267-3","volume":"13","author":"MY Sanchez-Contreras","year":"2018","unstructured":"Sanchez-Contreras MY, Kouri N, Cook CN, et al. Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Mol Neurodegener. 2018;13(1):37.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"884_CR26","doi-asserted-by":"publisher","first-page":"7880","DOI":"10.1038\/s41467-024-52025-x","volume":"15","author":"K Farrell","year":"2024","unstructured":"Farrell K, Humphrey J, Chang T, et al. Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genes. Nat Commun. 2024;15(1):7880.","journal-title":"Nat Commun"},{"key":"884_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.121758","volume":"455","author":"I Sghaier","year":"2023","unstructured":"Sghaier I, Nasri A, Frikha S, et al. Impact of MAPT haplotype on the phenotypic spectrum of progressive supranuclear palsy. J Neurol Sci. 2023;455:121758.","journal-title":"J Neurol Sci"},{"issue":"Pt 6","key":"884_CR28","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/brain\/awm104","volume":"130","author":"DR Williams","year":"2007","unstructured":"Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson\u2019s syndrome. Brain. 2007;130(Pt 6):1566\u201376.","journal-title":"Brain"},{"issue":"2","key":"884_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.14802\/jmd.20173","volume":"14","author":"HK Park","year":"2021","unstructured":"Park HK, Ilango SD, Litvan I. Environmental risk factors for progressive supranuclear palsy. J Mov Disord. 2021;14(2):103\u201313.","journal-title":"J Mov Disord"},{"key":"884_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.parkreldis.2019.07.036","volume":"66","author":"SV Rabadia","year":"2019","unstructured":"Rabadia SV, Litvan I, Juncos J, et al. Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord. 2019;66:166\u201370.","journal-title":"Parkinsonism Relat Disord"},{"key":"884_CR31","doi-asserted-by":"crossref","unstructured":"Chunowski P, Otto-Slusarczyk D, Duszynska-Was K, et al. Possible impact of peripheral inflammatory factors and interleukin-1beta (IL-1beta) on cognitive functioning in progressive supranuclear Palsy\u2013Richardson syndrome (PSP-RS) and progressive supranuclear palsy-predominant parkinsonism (PSP-P). Int J Mol Sci. 2024;25(23):13211.","DOI":"10.3390\/ijms252313211"},{"issue":"4","key":"884_CR32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00401-022-02479-4","volume":"144","author":"SF Roemer","year":"2022","unstructured":"Roemer SF, Grinberg LT, Crary JF, et al. Rainwater Charitable Foundation criteria for the neuropathologic diagnosis of progressive supranuclear palsy. Acta Neuropathol. 2022;144(4):603\u201314.","journal-title":"Acta Neuropathol"},{"issue":"12","key":"884_CR33","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/mds.27198","volume":"32","author":"S Koga","year":"2017","unstructured":"Koga S, Parks A, Kasanuki K, et al. Cognitive impairment in progressive supranuclear palsy is associated with tau burden. Mov Disord. 2017;32(12):1772\u20139.","journal-title":"Mov Disord"},{"key":"884_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.120718","volume":"451","author":"M Sakuwa","year":"2023","unstructured":"Sakuwa M, Adachi T, Suzuki Y, et al. Neuropathological analysis of cognitive impairment in progressive supranuclear palsy. J Neurol Sci. 2023;451:120718.","journal-title":"J Neurol Sci"},{"issue":"1","key":"884_CR35","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s40478-023-01674-y","volume":"11","author":"T Pansuwan","year":"2023","unstructured":"Pansuwan T, Quaegebeur A, Kaalund SS, et al. Accurate digital quantification of tau pathology in progressive supranuclear palsy. Acta Neuropathol Commun. 2023;11(1):178.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"884_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"884_CR37","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/mds.27038","volume":"32","author":"JL Whitwell","year":"2017","unstructured":"Whitwell JL, Hoglinger GU, Antonini A, et al. Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be? Mov Disord. 2017;32(7):955\u201371.","journal-title":"Mov Disord"},{"issue":"1","key":"884_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1600-0404.2006.00767.x","volume":"116","author":"M Cosottini","year":"2007","unstructured":"Cosottini M, Ceravolo R, Faggioni L, et al. Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging. Acta Neurol Scand. 2007;116(1):37\u201342.","journal-title":"Acta Neurol Scand"},{"key":"884_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.parkreldis.2016.05.006","volume":"28","author":"E Owens","year":"2016","unstructured":"Owens E, Krecke K, Ahlskog JE, et al. Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy. Parkinsonism Relat Disord. 2016;28:107\u201311.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"884_CR40","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1148\/radiol.2453061703","volume":"246","author":"A Quattrone","year":"2008","unstructured":"Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology. 2008;246(1):214\u201321.","journal-title":"Radiology"},{"issue":"4","key":"884_CR41","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10072-016-2489-x","volume":"37","author":"G Mostile","year":"2016","unstructured":"Mostile G, Nicoletti A, Cicero CE, et al. Magnetic resonance parkinsonism index in progressive supranuclear palsy and vascular parkinsonism. Neurol Sci. 2016;37(4):591\u20135.","journal-title":"Neurol Sci"},{"issue":"14","key":"884_CR42","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1002\/mds.23351","volume":"25","author":"A Hussl","year":"2010","unstructured":"Hussl A, Mahlknecht P, Scherfler C, et al. Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson\u2019s disease and the Parkinson variant of multiple system atrophy. Mov Disord. 2010;25(14):2444\u20139.","journal-title":"Mov Disord"},{"issue":"11","key":"884_CR43","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1212\/WNL.0b013e31822e55d0","volume":"77","author":"M Morelli","year":"2011","unstructured":"Morelli M, Arabia G, Novellino F, et al. MRI measurements predict PSP in unclassifiable parkinsonisms: a cohort study. Neurology. 2011;77(11):1042\u20137.","journal-title":"Neurology"},{"issue":"Pt 4","key":"884_CR44","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/brain\/awf082","volume":"125","author":"NJ Cordato","year":"2002","unstructured":"Cordato NJ, Pantelis C, Halliday GM, et al. Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain. 2002;125(Pt 4):789\u2013800.","journal-title":"Brain"},{"issue":"Pt 6","key":"884_CR45","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1093\/brain\/awh508","volume":"128","author":"NJ Cordato","year":"2005","unstructured":"Cordato NJ, Duggins AJ, Halliday GM, et al. Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. Brain. 2005;128(Pt 6):1259\u201366.","journal-title":"Brain"},{"issue":"6","key":"884_CR46","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.parkreldis.2013.02.005","volume":"19","author":"A Giordano","year":"2013","unstructured":"Giordano A, Tessitore A, Corbo D, et al. Clinical and cognitive correlations of regional gray matter atrophy in progressive supranuclear palsy. Parkinsonism Relat Disord. 2013;19(6):590\u20134.","journal-title":"Parkinsonism Relat Disord"},{"key":"884_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.parkreldis.2016.07.007","volume":"31","author":"F Caso","year":"2016","unstructured":"Caso F, Agosta F, Volonte MA, et al. Cognitive impairment in progressive supranuclear palsy-Richardson\u2019s syndrome is related to white matter damage. Parkinsonism Relat Disord. 2016;31:65\u201371.","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"884_CR48","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1212\/01.WNL.0000068011.21396.F4","volume":"60","author":"Y Tsuboi","year":"2003","unstructured":"Tsuboi Y, Slowinski J, Josephs KA, et al. Atrophy of superior cerebellar peduncle in progressive supranuclear palsy. Neurology. 2003;60(11):1766\u20139.","journal-title":"Neurology"},{"issue":"10","key":"884_CR49","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/j.neurobiolaging.2014.03.028","volume":"35","author":"A Tessitore","year":"2014","unstructured":"Tessitore A, Giordano A, Caiazzo G, et al. Clinical correlations of microstructural changes in progressive supranuclear palsy. Neurobiol Aging. 2014;35(10):2404\u201310.","journal-title":"Neurobiol Aging"},{"issue":"6248","key":"884_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/science.1255555","volume":"349","author":"M Goedert","year":"2015","unstructured":"Goedert M. Neurodegeneration. Alzheimer\u2019s and Parkinson\u2019s diseases: the prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science. 2015;349(6248):1255555.","journal-title":"Science"},{"issue":"2","key":"884_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae055","volume":"6","author":"V Planche","year":"2024","unstructured":"Planche V, Mansencal B, Manjon JV, et al. Staging of progressive supranuclear palsy-Richardson syndrome using MRI brain charts for the human lifespan. Brain Commun. 2024;6(2):fcae055.","journal-title":"Brain Commun"},{"key":"884_CR52","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ibneur.2024.04.008","volume":"16","author":"E Ichikawa-Escamilla","year":"2024","unstructured":"Ichikawa-Escamilla E, Velasco-Martinez RA, Adalid-Peralta L. Progressive supranuclear palsy syndrome: an overview. IBRO Neurosci Rep. 2024;16:598\u2013608.","journal-title":"IBRO Neurosci Rep"},{"issue":"6","key":"884_CR53","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2967\/jnumed.119.236224","volume":"61","author":"A Mueller","year":"2020","unstructured":"Mueller A, Bullich S, Barret O, et al. Tau PET imaging with (18)F-PI-2620 in patients with Alzheimer disease and healthy controls: a first-in-humans study. J Nucl Med. 2020;61(6):911\u20139.","journal-title":"J Nucl Med"},{"issue":"1","key":"884_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae458","volume":"7","author":"JR Winer","year":"2025","unstructured":"Winer JR, Vossler H, Young CB, et al. (18)F-PI-2620 tau PET is associated with cognitive and motor impairment in Lewy body disease. Brain Commun. 2025;7(1):fcae458.","journal-title":"Brain Commun"},{"issue":"11","key":"884_CR55","first-page":"1754","volume":"63","author":"K Messerschmidt","year":"2022","unstructured":"Messerschmidt K, Barthel H, Brendel M, et al. (18)F-PI-2620 Tau PET improves the imaging diagnosis of progressive supranuclear palsy. J Nucl Med. 2022;63(11):1754\u201360.","journal-title":"J Nucl Med"},{"issue":"8","key":"884_CR56","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/mds.20493","volume":"20","author":"RC Klein","year":"2005","unstructured":"Klein RC, de Jong BM, de Vries JJ, Leenders KL. Direct comparison between regional cerebral metabolism in progressive supranuclear palsy and Parkinson\u2019s disease. Mov Disord. 2005;20(8):1021\u201330.","journal-title":"Mov Disord"},{"issue":"3","key":"884_CR57","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/jnnp-2024-333590","volume":"96","author":"R Buchert","year":"2025","unstructured":"Buchert R, Huppertz HJ, Wegner F, et al. Added value of FDG-PET for detection of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2025;96(3):287\u201395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"884_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.675739","volume":"13","author":"KA Peterson","year":"2021","unstructured":"Peterson KA, Jones PS, Patel N, et al. Language disorder in progressive supranuclear palsy and corticobasal syndrome: neural correlates and detection by the MLSE screening tool. Front Aging Neurosci. 2021;13:675739.","journal-title":"Front Aging Neurosci"},{"issue":"1-2","key":"884_CR59","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jns.2006.01.006","volume":"244","author":"JH Im","year":"2006","unstructured":"Im JH, Chung SJ, Kim JS, Lee MC. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson\u2019s disease: analysis with [(123)I]IPT single photon emission computed tomography. J Neurol Sci. 2006;244(1\u20132):103\u20139.","journal-title":"J Neurol Sci"},{"issue":"4","key":"884_CR60","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/01.mnm.0000202858.45522.df","volume":"27","author":"L Filippi","year":"2006","unstructured":"Filippi L, Manni C, Pierantozzi M, et al. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson\u2019s disease: a SPECT semiquantitative study. Nucl Med Commun. 2006;27(4):381\u20136.","journal-title":"Nucl Med Commun"},{"issue":"4","key":"884_CR61","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1212\/WNL.0000000000207193","volume":"101","author":"D Alcolea","year":"2023","unstructured":"Alcolea D, Beeri MS, Rojas JC, et al. Blood biomarkers in neurodegenerative diseases: implications for the clinical neurologist. Neurology. 2023;101(4):172\u201380.","journal-title":"Neurology"},{"issue":"1","key":"884_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12014-024-09507-3","volume":"21","author":"Y Jang","year":"2024","unstructured":"Jang Y, Oh S, Hall AJ, et al. Biomarker discovery in progressive supranuclear palsy from human cerebrospinal fluid. Clin Proteom. 2024;21(1):56.","journal-title":"Clin Proteom"},{"issue":"4","key":"884_CR63","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1212\/WNL.0000000000004859","volume":"90","author":"JC Rojas","year":"2018","unstructured":"Rojas JC, Bang J, Lobach IV, et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018;90(4):e273\u201381.","journal-title":"Neurology"},{"key":"884_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.119975","volume":"565","author":"Y Chen","year":"2025","unstructured":"Chen Y, Huang J, Li Y, et al. Diagnostic value of six plasma biomarkers in progressive supranuclear palsy, multiple system atrophy, and Parkinson\u2019s disease. Clin Chim Acta. 2025;565:119975.","journal-title":"Clin Chim Acta"},{"issue":"4","key":"884_CR65","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/mds.29339","volume":"38","author":"SY Huang","year":"2023","unstructured":"Huang SY, Chen SF, Cui M, et al. Plasma biomarkers and positron emission tomography tau pathology in progressive supranuclear palsy. Mov Disord. 2023;38(4):676\u201382.","journal-title":"Mov Disord"},{"issue":"1","key":"884_CR66","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1038\/s41598-024-53355-y","volume":"14","author":"P Alster","year":"2024","unstructured":"Alster P, Otto-Slusarczyk D, Szlufik S, et al. The significance of glial cell line-derived neurotrophic factor analysis in progressive supranuclear palsy. Sci Rep. 2024;14(1):2805.","journal-title":"Sci Rep"},{"issue":"4","key":"884_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61040701","volume":"61","author":"A Giannakis","year":"2025","unstructured":"Giannakis A, Konitsiotis S, Sioka C. Differentiating progressive supranuclear palsy and corticobasal syndrome: insights from cerebrospinal fluid biomarkers-a narrative review. Medicina Kaunas. 2025;61(4):701.","journal-title":"Medicina Kaunas"},{"key":"884_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105807","volume":"117","author":"B Fernandes Gomes","year":"2023","unstructured":"Fernandes Gomes B, Farris CM, Ma Y, et al. alpha-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders. Parkinsonism Relat Disord. 2023;117:105807.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"884_CR69","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00401-025-02853-y","volume":"149","author":"AM Bernhardt","year":"2025","unstructured":"Bernhardt AM, Longen S, Trossbach SV, et al. A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson\u2019s disease. Acta Neuropathol. 2025;149(1):20.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"884_CR70","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00401-019-02080-2","volume":"139","author":"E Saijo","year":"2020","unstructured":"Saijo E, Metrick MA 2nd, Koga S, et al. 4-repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol. 2020;139(1):63\u201377.","journal-title":"Acta Neuropathol"},{"issue":"14","key":"884_CR71","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1002\/mds.26054","volume":"29","author":"G Respondek","year":"2014","unstructured":"Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord. 2014;29(14):1758\u201366.","journal-title":"Mov Disord"},{"issue":"Pt 6","key":"884_CR72","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/brain\/awm032","volume":"130","author":"LI Golbe","year":"2007","unstructured":"Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain. 2007;130(Pt 6):1552\u201365.","journal-title":"Brain"},{"key":"884_CR73","unstructured":"Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson\u2019s disease. In: Gillingham FJ, Donaldson MC, editors. Proceedings of the Third Symposium on Parkinson's Disease, 20\u201322 May 1968, Edinburgh. Edinburgh: Churchill Livingstone; 1969. p. 52\u2013157."},{"key":"884_CR74","unstructured":"Giagkou N, H\u00f6glinger G\u00fcnter U, Stamelou M. Chapter three\u2014progressive supranuclear palsy. Int Rev Neurobiol\n. 2019:149:49\u201386."},{"key":"884_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.804385","volume":"14","author":"P Krzosek","year":"2022","unstructured":"Krzosek P, Madetko N, Migda A, et al. Differential diagnosis of rare subtypes of progressive supranuclear palsy and PSP-like syndromes-infrequent manifestations of the most common form of atypical parkinsonism. Front Aging Neurosci. 2022;14:804385.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"884_CR76","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4103\/aian.AIAN_611_20","volume":"24","author":"RR Mahale","year":"2021","unstructured":"Mahale RR, Krishnan S, Divya KP, et al. Subtypes of PSP and prognosis: a retrospective analysis. Ann Indian Acad Neurol. 2021;24(1):56\u201362.","journal-title":"Ann Indian Acad Neurol"},{"issue":"5-6","key":"884_CR77","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1017\/S1355617725101215","volume":"31","author":"EA Boots","year":"2025","unstructured":"Boots EA, Weigand SD, Pham NTT, et al. Differences in neuropsychological performance across clinical variants of progressive supranuclear palsy. J Int Neuropsychol Soc. 2025;31(5\u20136):384\u201395.","journal-title":"J Int Neuropsychol Soc"},{"issue":"7","key":"884_CR78","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/archneur.1990.00530070035009","volume":"47","author":"J Blin","year":"1990","unstructured":"Blin J, Baron JC, Dubois B, et al. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol. 1990;47(7):747\u201352.","journal-title":"Arch Neurol"},{"issue":"4","key":"884_CR79","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00702-025-02890-7","volume":"132","author":"KA Jellinger","year":"2025","unstructured":"Jellinger KA. Pathomechanisms of neuropsychiatric disturbances in atypical parkinsonian disorders: a current view. J Neural Transm (Vienna). 2025;132(4):495\u2013518.","journal-title":"J Neural Transm (Vienna)"},{"issue":"2","key":"884_CR80","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s11065-022-09551-6","volume":"33","author":"S Raimo","year":"2023","unstructured":"Raimo S, Gaita M, Cropano M, et al. The cognitive profile of atypical Parkinsonism: a meta-analysis. Neuropsychol Rev. 2023;33(2):514\u201343.","journal-title":"Neuropsychol Rev"},{"issue":"2","key":"884_CR81","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac040","volume":"4","author":"D Backstrom","year":"2022","unstructured":"Backstrom D, Granasen G, Mo SJ, et al. Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study. Brain Commun. 2022;4(2):fcac040.","journal-title":"Brain Commun"},{"issue":"4","key":"884_CR82","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3233\/JAD-210023","volume":"80","author":"A Luca","year":"2021","unstructured":"Luca A, Nicoletti A, Donzuso G, et al. Phonemic verbal fluency and midbrain atrophy in progressive supranuclear palsy. J Alzheimers Dis. 2021;80(4):1669\u201374.","journal-title":"J Alzheimers Dis"},{"issue":"Suppl 3","key":"884_CR83","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1016\/S1353-8020(08)70028-2","volume":"13","author":"DJ Houghton","year":"2007","unstructured":"Houghton DJ, Litvan I. Unraveling progressive supranuclear palsy: from the bedside back to the bench. Parkinsonism Relat Disord. 2007;13(Suppl 3):S341-346.","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"884_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223621","volume":"14","author":"M Picillo","year":"2019","unstructured":"Picillo M, Cuoco S, Carotenuto I, et al. Clinical use of SAND battery to evaluate language in patients with progressive supranuclear palsy. PLoS ONE. 2019;14(10):e0223621.","journal-title":"PLoS ONE"},{"issue":"2","key":"884_CR85","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3233\/JAD-170743","volume":"61","author":"JR Burrell","year":"2018","unstructured":"Burrell JR, Ballard KJ, Halliday GM, Hodges JR. Aphasia in progressive supranuclear palsy: as severe as progressive non-fluent aphasia. J Alzheimers Dis. 2018;61(2):705\u201315.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"884_CR86","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.neuropsychologia.2006.01.002","volume":"44","author":"G Robinson","year":"2006","unstructured":"Robinson G, Shallice T, Cipolotti L. Dynamic aphasia in progressive supranuclear palsy: a deficit in generating a fluent sequence of novel thought. Neuropsychologia. 2006;44(8):1344\u201360.","journal-title":"Neuropsychologia"},{"issue":"7","key":"884_CR87","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","volume":"16","author":"AL Boxer","year":"2017","unstructured":"Boxer AL, Yu JT, Golbe LI, et al. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 2017;16(7):552\u201363.","journal-title":"Lancet Neurol"},{"issue":"4","key":"884_CR88","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/jnnp.60.4.403","volume":"60","author":"T Esmonde","year":"1996","unstructured":"Esmonde T, Giles E, Xuereb J, Hodges J. Progressive supranuclear palsy presenting with dynamic aphasia. J Neurol Neurosurg Psychiatry. 1996;60(4):403\u201310.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"884_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.635896","volume":"13","author":"ML Berthier","year":"2021","unstructured":"Berthier ML, Hoet F, Beltran-Corbellini A, et al. Case report: barely able to speak, can\u2019t stop echoing: echolalic dynamic aphasia in progressive supranuclear palsy. Front Aging Neurosci. 2021;13:635896.","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"884_CR90","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/07317115.2019.1694115","volume":"43","author":"TP Parthimos","year":"2020","unstructured":"Parthimos TP, Schulpis KH. The progressive supranuclear palsy: past and present aspects. Clin Gerontol. 2020;43(2):155\u201380.","journal-title":"Clin Gerontol"},{"issue":"3","key":"884_CR91","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/13854046.2019.1670865","volume":"34","author":"K Duff","year":"2020","unstructured":"Duff K, Randolph C, Boxer AL. Cognitive decline on the repeatable battery for the assessment of neuropsychological status in progressive supranuclear palsy. Clin Neuropsychol. 2020;34(3):529\u201340.","journal-title":"Clin Neuropsychol"},{"issue":"5","key":"884_CR92","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/13803395.2019.1572073","volume":"41","author":"K Duff","year":"2019","unstructured":"Duff K, McDermott D, Luong D, et al. Cognitive deficits in progressive supranuclear palsy on the repeatable battery for the assessment of neuropsychological status. J Clin Exp Neuropsychol. 2019;41(5):469\u201375.","journal-title":"J Clin Exp Neuropsychol"},{"issue":"11","key":"884_CR93","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00702-019-02065-1","volume":"126","author":"E Fiorenzato","year":"2019","unstructured":"Fiorenzato E, Antonini A, Camparini V, et al. Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson\u2019s disease. J Neural Transm. 2019;126(11):1437\u201345.","journal-title":"J Neural Transm"},{"issue":"5","key":"884_CR94","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/mds.25872","volume":"29","author":"JR Burrell","year":"2014","unstructured":"Burrell JR, Hodges JR, Rowe JB. Cognition in corticobasal syndrome and progressive supranuclear palsy: a review. Mov Disord. 2014;29(5):684\u201393.","journal-title":"Mov Disord"},{"issue":"9","key":"884_CR95","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1007\/s10072-022-06160-2","volume":"43","author":"AC Macedo","year":"2022","unstructured":"Macedo AC, Caramelli P, de Paula Franca Resende E, et al. Episodic memory in progressive supranuclear palsy: a neuropsychological and neuroimaging study. Neurol Sci. 2022;43(9):5363\u20138.","journal-title":"Neurol Sci"},{"issue":"5","key":"884_CR96","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1212\/WNL.47.5.1184","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology. 1996;47(5):1184\u20139.","journal-title":"Neurology"},{"issue":"3","key":"884_CR97","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/0891988721993545","volume":"35","author":"J Flavell","year":"2022","unstructured":"Flavell J, Nestor PJ. A systematic review of apathy and depression in progressive supranuclear palsy. J Geriatr Psychiatry Neurol. 2022;35(3):280\u201392.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"12","key":"884_CR98","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1212\/01.WNL.0000165977.38272.15","volume":"64","author":"B Dubois","year":"2005","unstructured":"Dubois B, Slachevsky A, Pillon B, et al. \u201cApplause sign\u201d helps to discriminate PSP from FTD and PD. Neurology. 2005;64(12):2132\u20133.","journal-title":"Neurology"},{"issue":"3","key":"884_CR99","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/nrn.2017.8","volume":"18","author":"JW Dalley","year":"2017","unstructured":"Dalley JW, Robbins TW. Fractionating impulsivity: neuropsychiatric implications. Nat Rev Neurosci. 2017;18(3):158\u201371.","journal-title":"Nat Rev Neurosci"},{"issue":"8","key":"884_CR100","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/jnnp.2010.224394","volume":"82","author":"S Luzzi","year":"2011","unstructured":"Luzzi S, Fabi K, Pesallaccia M, et al. Applause sign: is it really specific for Parkinsonian disorders? Evidence from cortical dementias. J Neurol Neurosurg Psychiatry. 2011;82(8):830\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"884_CR101","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.clineuro.2012.11.013","volume":"115","author":"J Somme","year":"2013","unstructured":"Somme J, Gomez-Esteban JC, Tijero B, et al. The applause sign and neuropsychological profile in progressive supranuclear palsy and Parkinson\u2019s disease. Clin Neurol Neurosurg. 2013;115(8):1230\u20133.","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"884_CR102","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000479110","volume":"17","author":"A Pilotto","year":"2017","unstructured":"Pilotto A, Gazzina S, Benussi A, et al. Mild cognitive impairment and progression to dementia in progressive supranuclear palsy. Neurodegener Dis. 2017;17(6):286\u201391.","journal-title":"Neurodegener Dis"},{"issue":"4","key":"884_CR103","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/mdc3.14315","volume":"12","author":"XY Li","year":"2025","unstructured":"Li XY, Yang YJ, Jiao FY, et al. Rapid cognitive deterioration in progressive supranuclear palsy: a 1-year follow-up study. Mov Disord Clin Pract. 2025;12(4):475\u201383.","journal-title":"Mov Disord Clin Pract"},{"issue":"5","key":"884_CR104","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/jnnp-2016-314956","volume":"88","author":"SA Glasmacher","year":"2017","unstructured":"Glasmacher SA, Leigh PN, Saha RA. Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(5):402\u201311.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"884_CR105","doi-asserted-by":"crossref","unstructured":"Sulena, Gupta D, Sharma AK, Kumar N. Clinical profile of cognitive decline in patients with Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy. J Neurosci Rural Pract. 2017;8(4):562\u20138.","DOI":"10.4103\/jnrp.jnrp_154_17"},{"issue":"1","key":"884_CR106","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2024-000946","volume":"7","author":"T Tsuboi","year":"2025","unstructured":"Tsuboi T, Tatsumi H, Kobayasi K, et al. Cognitive impairment in PSP compared with PD: assessment by clinical subtype and longitudinal change. BMJ Neurol Open. 2025;7(1):e000946.","journal-title":"BMJ Neurol Open"},{"issue":"4","key":"884_CR107","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/mds.25843","volume":"29","author":"I Litvan","year":"2014","unstructured":"Litvan I, Kong M. Rate of decline in progressive supranuclear palsy. Mov Disord. 2014;29(4):463\u20138.","journal-title":"Mov Disord"},{"issue":"9","key":"884_CR108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074486","volume":"8","author":"BC Ghosh","year":"2013","unstructured":"Ghosh BC, Carpenter RH, Rowe JB. A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy. PLoS ONE. 2013;8(9):e74486.","journal-title":"PLoS ONE"},{"key":"884_CR109","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/978-1-4471-6365-7_11","volume-title":"Movement disorders in dementias","author":"M Stamelou","year":"2014","unstructured":"Stamelou M, Bhatia K. Dementia in Parkinson\u2019s disease and atypical parkinsonism. In: Merello MJ, Starkstein SE, editors. Movement disorders in dementias. London: Springer; 2014. p. 179\u201397."},{"issue":"7","key":"884_CR110","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00415-019-09324-x","volume":"266","author":"M Picillo","year":"2019","unstructured":"Picillo M, Cuoco S, Tepedino MF, et al. Motor, cognitive and behavioral differences in MDS PSP phenotypes. J Neurol. 2019;266(7):1727\u201335.","journal-title":"J Neurol"},{"key":"884_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.694872","volume":"12","author":"B Bluett","year":"2021","unstructured":"Bluett B, Pantelyat AY, Litvan I, et al. Best practices in the clinical management of progressive supranuclear palsy and corticobasal syndrome: a consensus statement of the CurePSP centers of care. Front Neurol. 2021;12:694872.","journal-title":"Front Neurol"},{"key":"884_CR112","doi-asserted-by":"crossref","unstructured":"Priyanka, Qamar SH, Visanji NP. Toward an animal model of progressive supranuclear palsy. Front Neurosci. 2024;18:1433465.","DOI":"10.3389\/fnins.2024.1433465"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00884-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00884-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00884-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:02:07Z","timestamp":1772802127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00884-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["884"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00884-x","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marwan N. Sabbagh is a consultant for Alzheon, Athira, Biogen, Roche-Genentech, Eisai, Synaptogenix, NeuroTherapia, Cognito Therapeutics, Signant Health, and Novo Nordisk; is also an editorial board member of\n                      Neurology and Therapy\n                      , but was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Boris Decourt is a consultant for Lighthouse Pharmaceuticals. Nicki Niemann receives research support from The Michael J. Fox Foundation for Parkinson\u2019s Research, F. Hoffman-La Roche Ltd, Intra-Cellular Therapies Inc., Bial R&D Investments S.A., and Impax Laboratories LLC. Holly A. Shill has received research support from Intra-cellular Therapeutics, Parkinson Study Group\/UCB, Parkinson\u2019s Foundation, NINDS, MJFF, Jazz Pharmaceuticals, Fasikl, and Barrow Neurological Foundation. Holly A. Shill has served as a consultant for Biovie, Boston Scientific, Mitsubishi Tanabe, KeifeRx, Jazz, Fasikl, and Sumitomo. Kathleen S. Moore, Yara S. Stipho, Justine Chan, Crystal J. Abrego, and Danielle Eagan have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical Approval"}}]}}